PHP
SYRE icon

Parkman Healthcare Partners’s Spyre Therapeutics SYRE Stock Holding History

Parkman Healthcare Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-124,485
Closed -$4.08M – 110
2025
Q4 		$4.08M Sell
124,485
-76,268
-38% -$1.99M 0.39% 69
2025
Q3 		$3.36M Buy
+200,753
New +$3.27M 0.35% 73

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Parkman Healthcare Partners's SYRE Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 124,485 shares — an estimated $4.08M sold.

Parkman Healthcare Partners first reported a position in SYRE in Q3 2025 and held it in 2 quarters. The position peaked at $4.08M in Q4 2025. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Parkman Healthcare Partners reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 124,485 Spyre Therapeutics shares in Q1 2026, an estimated $4.08M.
  • Parkman Healthcare Partners first reported a position in Spyre Therapeutics in Q3 2025 and held it in 2 quarters.
  • Parkman Healthcare Partners's Spyre Therapeutics position peaked at $4.08M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.